Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG CBA-IFA with Reflex to Titer, Serum
Also known as: LGI1 IGG
Use
The test aids in the diagnosis of leucine-rich glioma inactivated 1 protein (LGI1) antibody disorders, such as limbic encephalitis, hyponatremia, and myoclonic movements. It is used to manage LGI1 antibody-positive individuals following immunotherapy and/or plasmapheresis. LGI1 IgG antibody presence is mainly associated with these neurological conditions and is rarely associated with tumors, though it may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy.
Special Instructions
If the LGI1 IgG antibody is positive, a titer will be added, and additional charges will apply. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings. This test is performed in a CLIA certified laboratory.
Limitations
LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in other conditions such as Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 82978-8
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.2 mL
Container
ARUP standard transport tube
Collection Instructions
Separate serum from cells within 2 hours of collection.
Storage Instructions
Refrigerated.
Causes for Rejection
CSF or plasma. Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |